Avacta Therapeutics (AIM: AVCT) has published preclinical data showing that its FAP-targeted payload delivery platform, FAP-Exd (AVA6103), outperforms the marketed antibody drug conjugate trastuzumab deruxtecan across three pharmacokinetic measures, with a Phase 1 clinical trial expected to begin in the first quarter of 2026.
What the AI-generated comparator actually enables
The methodological choice here deserves more scrutiny than the headline numbers. Rather than running a parallel in-house replication of AstraZeneca and Daiichi Sankyo’s published trastuzumab deruxtecan animal data, Avacta used an AI-generated synthetic comparator arm built from a 2024 paper by Vasalou and colleagues in CPT Pharmacometrics and Systems Pharmacology. This approach sidesteps the cost and time of wet-lab reproduction, but it also introduces a layer of modelling assumptions that peer reviewers and regulators will want to interrogate closely.
The legitimate value of the synthetic arm is that it enables a structured side-by-side read of two datasets that were never designed to be compared. The risk is that any divergence in animal model selection, dosing schedule, or assay methodology between the original AstraZeneca study and Avacta’s FAP-high model could systematically skew the pharmacokinetic ratios in either direction. Until the full dataset is published in a peer-reviewed journal, the three claimed advantages — faster tumor penetration, a log-higher tumor Cmax, and a nearly three-fold better Tumor Selectivity Index — are internally generated figures without independent validation. That does not make them wrong, but it limits their weight as competitive evidence at this stage.
Why tumor selectivity is the metric that matters most to the field
Of the three pharmacokinetic claims, the Tumor Selectivity Index is the one that oncology drug developers and regulators are most likely to focus on. The ratio of tumor-to-plasma drug exposure over fourteen days is a proxy for the therapeutic window: how much drug reaches the target tissue relative to systemic circulation, and therefore how much toxicity burden a patient carries per unit of anti-tumor effect.
Trastuzumab deruxtecan has delivered striking efficacy results across multiple solid tumor indications, including in patient populations previously considered HER2-low or HER2-ultralow. However, its toxicity profile, particularly interstitial lung disease and haematological adverse events, has been a persistent clinical concern. If Avacta’s platform genuinely delivers a three-fold improvement in the tumor-to-plasma AUC ratio under comparable dosing conditions, the implication is a meaningfully wider therapeutic window. That would be a commercially significant differentiator, not just a biological curiosity.
The FAP targeting rationale adds a further dimension. Fibroblast activation protein is expressed on cancer-associated fibroblasts in the tumor stroma rather than directly on cancer cells, which means the pre|CISION mechanism does not depend on receptor expression levels on the malignant cell population itself. Avacta’s scientists note higher FAP-Exd activity in tumor models with the lowest FAP expression compared to variable trastuzumab deruxtecan activity at low HER2 expression. If that holds in the clinic, it would address one of the central limitations of receptor-targeted ADCs: their declining efficacy as target expression falls below a functional threshold. That is a genuine differentiation point, not an incremental one, provided the preclinical observation translates.
The ADC competitive landscape this data is trying to disrupt
The antibody drug conjugate sector has undergone significant reappraisal over the past three years. Trastuzumab deruxtecan’s approvals in breast cancer and gastric cancer, combined with its exploratory results in lung and colorectal settings, established a new commercial benchmark. Several dozen ADC programs are now in clinical development globally, many using cleavable linker chemistry similar to the one deployed in trastuzumab deruxtecan.
Avacta is positioning the pre|CISION platform as a category alternative rather than a line extension within ADC chemistry. The core distinction is the activation mechanism: conventional ADCs rely on receptor-mediated internalization and intracellular linker cleavage, whereas pre|CISION is designed for extracellular cleavage by FAP expressed in the tumor microenvironment. The claimed faster tumor penetration and higher Cmax, with maximum concentration reached in minutes rather than twenty-four hours, would be a direct consequence of extracellular release bypassing the internalization step entirely.
Industry observers tracking the payload delivery space will note that extracellular cleavage strategies carry their own risk profile. Payload released into the extracellular space before cellular uptake could, under some conditions, diffuse into adjacent normal tissue. Avacta’s Tumor Selectivity Index data argues against this concern in their model, but the mechanism requires careful characterization across tumor types with varying stromal density and FAP expression patterns before broad claims can be made.
What Phase 1 design choices will define credibility
The imminent Phase 1 trial of FAP-Exd is where the preclinical narrative will either gain traction or face its first hard test. Several design decisions will determine how informative the early clinical data is.
Patient selection criteria will be watched closely. FAP expression is heterogeneous across tumor types and even within individual tumors, and the level of FAP required for meaningful pre|CISION activation in a clinical setting has not yet been publicly defined. If the trial enrolls a broad, unselected population, early response data will be difficult to interpret. A biomarker-stratified design would be scientifically stronger but operationally more demanding for a small clinical-stage company.
The safety endpoints will also carry disproportionate weight given Avacta’s mechanistic claims about selectivity. If the improved Tumor Selectivity Index seen preclinically translates into a genuinely cleaner adverse event profile compared to published trastuzumab deruxtecan data, that will be a meaningful signal for both regulators and potential partnership conversations. If systemic toxicity appears at therapeutically relevant doses, it would raise questions about the degree to which the preclinical model captured human pharmacokinetics accurately.
Avacta is a relatively small AIM-listed company without the internal resources to run a large Phase 1 and simultaneously advance manufacturing scale-up and partnership discussions. The publication of this comparative data ahead of trial initiation reads in part as a signal to potential partners or acquirers, framing AVA6103 within a commercially legible benchmark. How that commercial positioning affects trial design discipline is something industry observers will track.
Regulatory and translational risks that remain unresolved
FAP-targeted therapies have a longer development history than their current profile might suggest. Earlier FAP-directed approaches, including FAP-targeted immunotherapies and imaging agents, produced mixed translational results partly because FAP biology in human tumors is more variable than preclinical models reflect. Avacta’s platform is delivering a cytotoxic payload rather than engaging the immune system, which changes the translational calculus, but the underlying variability of FAP expression in patient populations remains a genuine uncertainty.
Regulatory watchers will note that the synthetic comparator methodology, while creative, has no established precedent in a regulatory submission context. The data being generated now is preclinical and the AI comparison will likely feature in investigational new drug filings and early scientific presentations, but it will not be accepted as a substitute for clinical comparator data further down the development pathway. Avacta will need prospective clinical evidence to substantiate the competitive claims made today.
The peer-reviewed publication and planned scientific congress presentation will be the next significant credibility checkpoints. How the data survives external scrutiny of the AI methodology and the animal model assumptions will materially affect how the field receives the clinical trial results when they begin to emerge.
Avacta (AIM: AVCT) FAP-Exd data challenges Enhertu on tumor selectivity ahead of Phase 1 start added by Pallavi Madhiraju on
View all posts by Pallavi Madhiraju →